{"analyses":[{"ciLowerLimit":"0.5","ciPctValue":"95","ciUpperLimit":"5.0","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":".41","paramType":"Hazard Ratio (HR)","paramValue":"1.62","statisticalMethod":"Regression, Cox","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"77"}],"units":"Participants"}],"description":"Death without prior development of recurrent malignancy","groups":[{"description":"Patients receive oral mycophenolate mofetil 1000 mg twice daily.","id":"OG000","title":"Mycophenolate Mofetil"},{"description":"Patients receive oral placebo twice daily","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"within 4 years","title":"Non-relapse Mortality","type":"SECONDARY","unitOfMeasure":"participants"}